Enzo Biochem (NYSE:ENZ) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a report issued on Wednesday morning. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

NYSE:ENZ opened at $0.73 on Wednesday. Enzo Biochem has a 12-month low of $0.68 and a 12-month high of $1.50. The business has a 50 day simple moving average of $1.03 and a 200 day simple moving average of $1.09.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative net margin of 81.73% and a negative return on equity of 11.84%.

Enzo Biochem Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 15th were given a dividend of $0.10 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.40 annualized dividend and a dividend yield of 54.95%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Geode Capital Management LLC grew its position in Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after buying an additional 11,742 shares in the last quarter. BBR Partners LLC bought a new position in shares of Enzo Biochem in the third quarter valued at approximately $112,000. XTX Topco Ltd increased its stake in shares of Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 13,735 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares in the last quarter. 36.90% of the stock is owned by institutional investors and hedge funds.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.